Lannapril Plus Forte

Hydrochlorothiazide and Ramipril, the active ingredient in Lannapril Plus Forte, is a combination ACE inhibitor and thiazide diuretic presented as an oral tablet for systemic use. It is indicated for the management of hypertension and as adjunct therapy in heart failure, acting to lower blood pressure and reduce fluid overload.

GNH USA supplies Lannapril Plus Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lannapril Plus Forte combines an ACE‑inhibitor and a thiazide diuretic to treat cardiovascular conditions. - Hypertension: lowers systolic and diastolic pressure by vasodilation and reduced plasma volume. - Heart failure (adjunct therapy): improves symptoms by decreasing preload and afterload, supporting cardiac output. - Left ventricular dysfunction: helps remodel cardiac tissue by reducing neurohormonal activation.

Lannapril Plus Forte may cause a range of adverse reactions.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Increased urination or nocturia. - Electrolyte disturbances such as low potassium. - Mild headache. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: rise in serum creatinine or reduced urine output. - Hyperkalemia: dangerously high potassium levels. - Severe electrolyte imbalance: hyponatremia or metabolic alkalosis. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Lannapril Plus Forte, clinicians should evaluate patient history and laboratory values. - Renal function: assess creatinine clearance; dose may need adjustment in impairment. - Electrolytes: monitor potassium and sodium levels regularly. - Pregnancy: contraindicated in the second and third trimesters (Category D). - Concomitant potassium‑sparing agents: avoid to reduce hyperkalemia risk. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lannapril Plus Forte interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Lithium: increased lithium levels leading to toxicity. - NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and worsen renal function. - Potassium‑sparing diuretics or supplements: risk of severe hyperkalemia. - Aliskiren (in diabetics): combined renin‑angiotensin blockade can cause renal impairment.

Moderate Interactions (Monitor Closely): - ACE inhibitor or ARB combinations: monitor blood pressure and renal function. - Diuretics other than hydrochlorothiazide: adjust electrolytes and volume status. - Antidiabetic agents (e.g., insulin, sulfonylureas): may need dose adjustment due to altered glucose control. - Antihypertensive agents (beta‑blockers, calcium channel blockers): watch for additive hypotensive effects.